Position in APGE
as of Jun 30, 2026
· filed Aug 5, 2026
Position Value
$354,920
-$155,402 QoQ
Shares Held
2,674
-55.9% QoQ
Ownership
0.004%
of shares outstanding
% of Portfolio
0.33%
of 13F equity value
Holder Rank
#213
of 281 holders
Holding Since
Mar 2026
2 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in APGE Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Bayforest Capital Ltd holds $6,768,179 across 52 Biotechnology names. APGE ranks #4 (5.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | RCUS |
Arcus Biosciences, Inc.
|
12,709 | $391,818 | |
| 2 | BEAM |
Beam Therapeutics Inc.
|
10,740 | $368,596 | |
| 3 | VRDN |
Viridian Therapeutics, Inc.\DE
|
19,775 | $363,266 | |
| 4 | APGE |
Apogee Therapeutics, Inc.
This page
|
2,674 | $354,920 | |
| 5 | PTGX |
Protagonist Therapeutics, Inc
|
2,675 | $327,901 | |
| 6 | DNLI |
Denali Therapeutics Inc.
|
11,437 | $294,159 | |
| 7 | WVE |
Wave Life Sciences Ltd.
|
48,854 | $283,841 | |
| 8 | ARWR |
Arrowhead Pharmaceuticals, Inc.
|
3,311 | $269,879 |
All Filings in APGE
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $354,920 | 2,674 | Shares | Sole | 2026-08-05 | |
| 2026-03-31 | $510,322 | 6,063 | Shares | Sole | 2026-04-15 | |
| No filing history on record for this holder in this stock. | ||||||